Estimating (quality‐adjusted) life‐year losses associated with deaths: With application to COVID‐19
Many epidemiological models of the COVID‐19 pandemic have focused on preventing
deaths. Questions have been raised as to the frailty of those succumbing to the COVID‐19 …
deaths. Questions have been raised as to the frailty of those succumbing to the COVID‐19 …
[HTML][HTML] Vaccine rollout strategies: The case for vaccinating essential workers early
In vaccination campaigns against COVID-19, many jurisdictions are using age-based rollout
strategies, reflecting the much higher risk of severe outcomes of infection in older groups. In …
strategies, reflecting the much higher risk of severe outcomes of infection in older groups. In …
Damping of flexural waves by a constrained viscoelastic layer
EM Kerwin Jr - The Journal of the Acoustical society of America, 1959 - pubs.aip.org
… (However E2 must be large enough to satisfy assumption e.) (e) Layer 2 is assumed to hold
… stress is the product of strain and elastic modulus (E). The average stress on layer 1 is the …
… stress is the product of strain and elastic modulus (E). The average stress on layer 1 is the …
Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial
…, N Kara, S Karpischenko, E Kerwin… - The Lancet …, 2021 - thelancet.com
Background Chronic rhinosinusitis with nasal polyps affects approximately 2–4% of the
general population, and long-term use of systemic corticosteroids is associated with adverse …
general population, and long-term use of systemic corticosteroids is associated with adverse …
Randomized, double-blind, placebo-controlled study of brodalumab, a human anti–IL-17 receptor monoclonal antibody, in moderate to severe asthma
Rationale: IL-17 signaling has been implicated in development and persistence of asthma.
Cytokine-targeted strategies blocking IL-17 receptor signaling may be beneficial in asthma …
Cytokine-targeted strategies blocking IL-17 receptor signaling may be beneficial in asthma …
A randomized, double-blind, placebo-controlled study of tumor necrosis factor-α blockade in severe persistent asthma
Rationale: The treatment effect of golimumab, a human monoclonal antibody against tumor
necrosis factor (TNF)-α, in severe persistent asthma is unknown. Objectives: To assess the …
necrosis factor (TNF)-α, in severe persistent asthma is unknown. Objectives: To assess the …
Loss factors of viscoelastic systems in terms of energy concepts
EE Ungar, EM Kerwin Jr - The Journal of the acoustical Society of …, 1962 - pubs.aip.org
The definition of loss factor in terms of energy quantities is reexamined, particularly as it
applies to composite viscoelastic systems. A restatement of this definition in terms of a …
applies to composite viscoelastic systems. A restatement of this definition in terms of a …
[HTML][HTML] A conceptual framework for life-cycle health technology assessment
Objectives Health technology assessment (HTA) uses evidence appraisal and synthesis
with economic evaluation to inform adoption decisions. Standard HTA processes sometimes …
with economic evaluation to inform adoption decisions. Standard HTA processes sometimes …
Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study
E Kerwin, J Hébert, N Gallagher… - European …, 2012 - Eur Respiratory Soc
NVA237 (glycopyrronium bromide) is a once-daily long-acting muscarinic antagonist (LAMA)
in development for chronic obstructive pulmonary disease (COPD). The GLycopyrronium …
in development for chronic obstructive pulmonary disease (COPD). The GLycopyrronium …
Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive …
Background Combination long-acting bronchodilator treatment might be more effective than
long-acting bronchodilator monotherapy for the treatment of chronic obstructive pulmonary …
long-acting bronchodilator monotherapy for the treatment of chronic obstructive pulmonary …